2019
Thirty-Day Readmissions in Patients With Metastatic Cancer: Room for Improvement?
Solomon R, Egorova N, Adelson K, Smith CB, Franco R, Bickell NA. Thirty-Day Readmissions in Patients With Metastatic Cancer: Room for Improvement? JCO Oncology Practice 2019, 15: e410-e419. PMID: 30925070, DOI: 10.1200/jop.18.00500.Peer-Reviewed Original ResearchConceptsHigher readmission ratesReadmission ratesMetastatic cancerPreventable readmissionsTeaching hospitalNew York State hospital dischargesThirty-day readmissionState hospital dischargeSkilled nursing facilitiesCompeting-risks modelReadmission likelihoodAdvanced diseaseDischarge homeDischarge dispositionHospital dischargeYounger patientsReadmission reduction effortsHospice dischargeFemale sexHospital typeReadmissionNursing facilitiesPatientsHealth needsYounger age
2018
Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database
Chang E, Mougalian SS, Adelson KB, Young MR, Yu JB. Association between prolonged metastatic free interval and recurrent metastatic breast cancer survival: findings from the SEER database. Breast Cancer Research And Treatment 2018, 173: 209-216. PMID: 30242577, DOI: 10.1007/s10549-018-4968-7.Peer-Reviewed Original ResearchConceptsMetastatic-free intervalMetastatic breast cancerInitial breast cancer diagnosisBreast cancer-specific mortalityCancer-specific mortalitySubsequent metastatic diseaseBreast cancer diagnosisMetastatic diseaseFree intervalBreast cancerCancer diagnosisBreast cancer-specific survival ratesMetastatic breast cancer survivalCancer-specific survival ratesDiagnosis of MBCImproved cancer-specific survivalRecurrent metastatic breast cancerCancer-specific survivalEnd Results (SEER) databaseLow tumor gradeBreast cancer survivalChoice of treatmentStratification of patientsMethodsThe SurveillancePurposeThe prevalence
2017
Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer
Adelson K, Lee DKK, Velji S, Ma J, Lipka SK, Rimar J, Longley P, Vega T, Perez-Irizarry J, Pinker E, Lilenbaum R. Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer. JCO Oncology Practice 2017, 14: jop.2017.023200. PMID: 29206553, DOI: 10.1200/jop.2017.023200.Peer-Reviewed Original ResearchConceptsShort-term mortalityAdvanced cancerChance of deathLife carePrognostic toolNovel prognostic toolObjective prognostic toolSmilow Cancer HospitalDay of admissionElectronic health record dataMedian survival timeSubjective clinical assessmentHealth record dataPositive predictive valueMedian survivalHospitalized patientsMortality predictorsCancer HospitalPrognostication toolsClinical assessmentSurvival timePatientsPredictive valueCancerMortality
2015
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson HG, Bao Y, Shah MA, Paulk ME, LeBlanc TW, Schneider BJ, Garrido MM, Reid MC, Berlin DA, Adelson KB, Neugut AI, Maciejewski PK. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. JAMA Oncology 2015, 1: 778-784. PMID: 26203912, PMCID: PMC4828728, DOI: 10.1001/jamaoncol.2015.2378.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChi-Square DistributionFemaleHealth StatusHealth Status IndicatorsHumansLogistic ModelsLongitudinal StudiesMaleMiddle AgedMultivariate AnalysisNeoplasm MetastasisNeoplasm StagingNeoplasmsOdds RatioPalliative CarePatient SelectionProportional Hazards ModelsProspective StudiesQuality of LifeRisk AssessmentRisk FactorsStress, PsychologicalSurveys and QuestionnairesTerminal CareTime FactorsTreatment OutcomeUnited StatesConceptsEnd-stage cancerGood performance statusBaseline performance statusQuality of lifeChemotherapy usePatient performance statusPerformance statusPalliative chemotherapyEastern Cooperative Oncology Group performance statusGood baseline performance statusPoor baseline performance statusProgressive metastatic cancerProgressive metastatic diseasePoor performance statusSolid tumor patientsClinical Oncology guidelinesLongitudinal cohort studyOutpatient oncology clinicsChemotherapy regimenEnd of lifeCohort studyMetastatic diseaseOncology clinicPatient survivalOncology guidelines